SALICINIUM
DEAD

Serial Number

85102816

Owner

COGNATE 3 LLC

Attorney

Jeffrey J. King

First Use Date

Feb 10, 2009

Filing Date

Aug 9, 2010

Add to watchlist:

No watchlists yet
View on USPTO

SALICINIUM Trademark

Serial Number: 85102816 • Registration: 4123876

SALICINIUM is a trademark filed by COGNATE 3 LLC on August 9, 2010. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

COGNATE 3 LLC (2 trademarks)

218 MAIN STREET
KIRKLAND, WA 98033

Entity Type: 03

Trademark Details

Filing Date

August 9, 2010

Registration Date

April 10, 2012

First Use Anywhere

February 10, 2009

First Use in Commerce

February 10, 2009

Published for Opposition

January 24, 2012

Cancellation Date

November 16, 2018

Goods & Services

Drug preparations, liquid drug formulations, prescription and non-prescription medications, namely, capsules, tablets, powders, and pharmaceutical preparations, injectable pharmaceuticals, topical formulations and patches, infusion pharmaceutical preparations, intravenous pharmaceutical formulations, and pharmaceutical solutions for medical and nutritional purposes and uses, namely, for treatment of immune disorders, immune deficiencies, cellular proliferative disorders, namely, cancer, bacterial, viral and fungal infections, physiological pH imbalances, digestive disorders, and nutritional and dietary deficiencies; Drugs and medications namely, anti-inflammatories, pharmaceutical preparations used in cancer therapeutics, antiseptics, antibiotics, antivirals, antifungal preparations, antimicrobial preservatives for cosmetics and pharmaceuticals, pharmaceutical preparations for the treatment of immune system related diseases and disorders, immune supplemental, nutritional supplements for stimulating the immunity system, pharmaceutical preparations for wound healing, nutritional supplements for balancing immune system-related factors, namely, blood sugar and pH levels, nutritional supplements for adjusting and balancing pH levels and other immune system-related factors, and dietary supplements and balancing drugs and medications, namely, medications incorporating active drugs and other therapeutic agents effective for alleviating immune disorders, immune deficiencies, cellular proliferative disorders, physiological pH imbalances, digestive disorders, and nutritional and dietary deficiencies, all for oral, topical, intravenous, injection and infusion therapy

Filing History

CANCELLED SEC. 8 (6-YR)
Nov 16, 2018 C8..
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Apr 10, 2017 REM1
REGISTERED-PRINCIPAL REGISTER
Apr 10, 2012 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 24, 2012 NPUB
PUBLISHED FOR OPPOSITION
Jan 24, 2012 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 4, 2012 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Dec 17, 2011 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 12, 2011 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 12, 2011 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 12, 2011 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 12, 2011 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 12, 2011 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Dec 10, 2011 GNFN
FINAL REFUSAL E-MAILED
Dec 10, 2011 GNFR
FINAL REFUSAL WRITTEN
Dec 10, 2011 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 19, 2011 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 19, 2011 CRFA
ASSIGNED TO LIE
Nov 14, 2011 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 31, 2011 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 29, 2011 GNRN
NON-FINAL ACTION E-MAILED
Apr 29, 2011 GNRT
NON-FINAL ACTION WRITTEN
Apr 29, 2011 CNRT
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 13, 2010 GNRN
NON-FINAL ACTION E-MAILED
Sep 13, 2010 GNRT
NON-FINAL ACTION WRITTEN
Sep 13, 2010 CNRT
ASSIGNED TO EXAMINER
Sep 13, 2010 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 12, 2010 NWOS
NEW APPLICATION ENTERED
Aug 12, 2010 NWAP